Premium
Clinical presentation, treatment and outcome in 31 dogs with presumed primary colorectal lymphoma (2001–2013)
Author(s) -
Desmas I.,
Burton J. H.,
Post G.,
Kristal O.,
Gauthier M.,
Borrego J. F.,
Di Bella A.,
LaraGarcia A.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12194
Subject(s) - medicine , chemotherapy , lymphoma , retrospective cohort study , presentation (obstetrics) , radiation therapy , surgery , immunophenotyping , gastroenterology , immunology , antigen
The objective of this multicentre retrospective study was to describe clinical presentation, treatment and outcome and to determine prognostic factors for dogs with presumed primary colorectal lymphoma ( PCRL ). A total of 31 dogs were included. The predominant features of PCRL were high grade ( n = 18) and immunophenotype B ( n = 24). Most dogs were substage b ( n = 25) with higher prevalence of haematochezia ( n = 20). One dog had surgery only. Thirty dogs received chemotherapy; amongst them 13 had surgery or radiotherapy. Progression free survival ( PFS ) was 1318 days and disease‐related median survival time ( MST ) was 1845 days. Fourteen dogs were alive at the end of the study with a median follow‐up time of 684 days (3–4678 days). Younger dogs had longer PFS ( P = 0.031) and disease‐related MST ( P = 0.01). Presence of haematochezia corresponded with longer PFS ( P = 0.02). Addition of local treatment to chemotherapy did not significantly improve the outcome ( P = 0.584). Canine PCRL has considerably longer PFS and MST than other forms of non‐Hodgkin's lymphoma.